189 related articles for article (PubMed ID: 36793213)
21. Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release.
Zuch de Zafra CL; Fajardo F; Zhong W; Bernett MJ; Muchhal US; Moore GL; Stevens J; Case R; Pearson JT; Liu S; McElroy PL; Canon J; Desjarlais JR; Coxon A; Balazs M; Nolan-Stevaux O
Clin Cancer Res; 2019 Jul; 25(13):3921-3933. PubMed ID: 30918018
[TBL] [Abstract][Full Text] [Related]
22. B7-H3×4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8
You G; Lee Y; Kang YW; Park HW; Park K; Kim H; Kim YM; Kim S; Kim JH; Moon D; Chung H; Son W; Jung UJ; Park E; Lee S; Son YG; Eom J; Won J; Park Y; Jung J; Lee SW
Sci Adv; 2021 Jan; 7(3):. PubMed ID: 33523913
[TBL] [Abstract][Full Text] [Related]
23. Combination therapy with B7H3-redirected bispecific antibody and Sorafenib elicits enhanced synergistic antitumor efficacy.
Huang C; Li H; Feng Y; Li X; Zhang Z; Jiang C; Wang J; Yang C; Fu Y; Mu M; Zhao S; Wang Z; Kuang Y; Hou H; Wang Y; Guo W; Xu J; Yang H; Zhou L; Tong A; Guo G
Theranostics; 2020; 10(23):10498-10512. PubMed ID: 32929362
[No Abstract] [Full Text] [Related]
24. A Novel T Cell-Engaging Bispecific Antibody for Treating Mesothelin-Positive Solid Tumors.
Yoon A; Lee S; Lee S; Lim S; Park YY; Song E; Kim DS; Kim K; Lim Y
Biomolecules; 2020 Mar; 10(3):. PubMed ID: 32143496
[TBL] [Abstract][Full Text] [Related]
25. Affinity Maturation of B7-H6 Translates into Enhanced NK Cell-Mediated Tumor Cell Lysis and Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement.
Pekar L; Klausz K; Busch M; Valldorf B; Kolmar H; Wesch D; Oberg HH; Krohn S; Boje AS; Gehlert CL; Toleikis L; Krah S; Gupta T; Rabinovich B; Zielonka S; Peipp M
J Immunol; 2021 Jan; 206(1):225-236. PubMed ID: 33268483
[TBL] [Abstract][Full Text] [Related]
26. Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on mesothelin-positive tumors.
Hatterer E; Chauchet X; Richard F; Barba L; Moine V; Chatel L; Broyer L; Pontini G; Bautzova T; Juan F; Calloud S; Bosson N; Charreton M; Masternak K; Buatois V; Shang L
MAbs; 2020; 12(1):1739408. PubMed ID: 32191151
[TBL] [Abstract][Full Text] [Related]
27. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
Katzenwadel A; Schleer H; Gierschner D; Wetterauer U; Elsässer-Beile U
Anticancer Res; 2000; 20(3A):1551-5. PubMed ID: 10928069
[TBL] [Abstract][Full Text] [Related]
28. Suppression of c-Met-Overexpressing Tumors by a Novel c-Met/CD3 Bispecific Antibody.
Huang L; Xie K; Li H; Wang R; Xu X; Chen K; Gu H; Fang J
Drug Des Devel Ther; 2020; 14():3201-3214. PubMed ID: 32982167
[TBL] [Abstract][Full Text] [Related]
29. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.
Lutterbuese R; Raum T; Kischel R; Lutterbuese P; Schlereth B; Schaller E; Mangold S; Rau D; Meier P; Kiener PA; Mulgrew K; Oberst MD; Hammond SA; Baeuerle PA; Kufer P
J Immunother; 2009 May; 32(4):341-52. PubMed ID: 19342971
[TBL] [Abstract][Full Text] [Related]
30. GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma.
Zirngibl F; Ivasko SM; Grunewald L; Klaus A; Schwiebert S; Ruf P; Lindhofer H; Astrahantseff K; Andersch L; Schulte JH; Lode HN; Eggert A; Anders K; Hundsdoerfer P; Künkele A
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34285106
[TBL] [Abstract][Full Text] [Related]
31. A CD3-bispecific molecule targeting P-cadherin demonstrates T cell-mediated regression of established solid tumors in mice.
Fisher TS; Hooper AT; Lucas J; Clark TH; Rohner AK; Peano B; Elliott MW; Tsaparikos K; Wang H; Golas J; Gavriil M; Haddish-Berhane N; Tchistiakova L; Gerber HP; Root AR; May C
Cancer Immunol Immunother; 2018 Feb; 67(2):247-259. PubMed ID: 29067496
[TBL] [Abstract][Full Text] [Related]
32. Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials.
Hosseini SS; Khalili S; Baradaran B; Bidar N; Shahbazi MA; Mosafer J; Hashemzaei M; Mokhtarzadeh A; Hamblin MR
Int J Biol Macromol; 2021 Jan; 167():1030-1047. PubMed ID: 33197478
[TBL] [Abstract][Full Text] [Related]
33. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas.
Oberst MD; Fuhrmann S; Mulgrew K; Amann M; Cheng L; Lutterbuese P; Richman L; Coats S; Baeuerle PA; Hammond SA
MAbs; 2014; 6(6):1571-84. PubMed ID: 25484061
[TBL] [Abstract][Full Text] [Related]
34. Single-domain antibody-based and linker-free bispecific antibodies targeting FcγRIII induce potent antitumor activity without recruiting regulatory T cells.
Rozan C; Cornillon A; Pétiard C; Chartier M; Behar G; Boix C; Kerfelec B; Robert B; Pèlegrin A; Chames P; Teillaud JL; Baty D
Mol Cancer Ther; 2013 Aug; 12(8):1481-91. PubMed ID: 23757164
[TBL] [Abstract][Full Text] [Related]
35. A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells.
Yu S; Zhang J; Yan Y; Yao X; Fang L; Xiong H; Liu Y; Chu Q; Zhou P; Wu K
J Exp Clin Cancer Res; 2019 Aug; 38(1):355. PubMed ID: 31412896
[TBL] [Abstract][Full Text] [Related]
36. Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1.
Qi J; Li X; Peng H; Cook EM; Dadashian EL; Wiestner A; Park H; Rader C
Proc Natl Acad Sci U S A; 2018 Jun; 115(24):E5467-E5476. PubMed ID: 29844189
[TBL] [Abstract][Full Text] [Related]
37. Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies.
Trinklein ND; Pham D; Schellenberger U; Buelow B; Boudreau A; Choudhry P; Clarke SC; Dang K; Harris KE; Iyer S; Jorgensen B; Pratap PP; Rangaswamy US; Ugamraj HS; Vafa O; Wiita AP; van Schooten W; Buelow R; Force Aldred S
MAbs; 2019; 11(4):639-652. PubMed ID: 30698484
[TBL] [Abstract][Full Text] [Related]
38. In vitro and in vivo antitumor effects of recombinant bispecific antibodies based on humanized anti-EGFR antibody.
Watanabe Y; Asano R; Arai K; Shimomura I; Ogata H; Kawaguchi H; Hayashi H; Ohtsuka H; Yoshida H; Katayose Y; Egawa S; Nakanishi T; Umetsu M; Yasui H; Ishida T; Imai K; Kudo T; Unno M; Kumagai I
Oncol Rep; 2011 Oct; 26(4):949-55. PubMed ID: 21743971
[TBL] [Abstract][Full Text] [Related]
39. A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma.
Gedeon PC; Schaller TH; Chitneni SK; Choi BD; Kuan CT; Suryadevara CM; Snyder DJ; Schmittling RJ; Szafranski SE; Cui X; Healy PN; Herndon JE; McLendon RE; Keir ST; Archer GE; Reap EA; Sanchez-Perez L; Bigner DD; Sampson JH
Clin Cancer Res; 2018 Aug; 24(15):3611-3631. PubMed ID: 29703821
[No Abstract] [Full Text] [Related]
40. A new class of bispecific antibodies to redirect T cells for cancer immunotherapy.
Rossi DL; Rossi EA; Cardillo TM; Goldenberg DM; Chang CH
MAbs; 2014; 6(2):381-91. PubMed ID: 24492297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
